HC Wainwright Forecasts Lower Earnings for Solid Biosciences

Key Points

• HC Wainwright has lowered its Q3 2025 earnings per share (EPS) estimates for Solid Biosciences, now forecasting a loss of ($0.45) per share, down from ($0.43).
• Several analysts have reduced their price targets for Solid Biosciences, with Barclays setting a new target at $10.00, down from $15.00.
• Solid Biosciences shares opened at $6.17 and have a market capitalization of $480.46 million, with an average rating of "Buy" according to market data.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for shares of Solid Biosciences in a report issued on Wednesday, August 13th. HC Wainwright analyst A. He now expects that the company will post earnings per share of ($0.45) for the quarter, down from their previous forecast of ($0.43). HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences' Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.87) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.54) EPS, FY2026 earnings at ($2.01) EPS, FY2027 earnings at ($1.75) EPS and FY2028 earnings at ($0.78) EPS.

Other analysts have also recently issued reports about the company. Barclays reduced their price target on Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating on the stock in a report on Friday, May 16th. JMP Securities restated a "market outperform" rating and set a $15.00 price target on shares of Solid Biosciences in a report on Friday, June 6th. Wedbush reduced their price target on Solid Biosciences from $17.00 to $14.00 and set an "outperform" rating on the stock in a report on Wednesday. JPMorgan Chase & Co. reduced their target price on Solid Biosciences from $15.00 to $13.00 and set an "overweight" rating on the stock in a report on Thursday. Finally, Piper Sandler decreased their target price on Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating for the company in a research note on Friday, May 16th. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $15.00.

Solid Biosciences Trading Down 7.6%

Shares of NASDAQ SLDB opened at $6.17 on Friday. The company has a market cap of $480.46 million, a price-to-earnings ratio of -2.20 and a beta of 2.44. The stock has a 50-day moving average price of $5.59 and a two-hundred day moving average price of $4.41. Solid Biosciences has a 12 month low of $2.41 and a 12 month high of $10.37.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09.

Hedge Funds Weigh In On Solid Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of SLDB. CWM LLC boosted its stake in Solid Biosciences by 15,188.5% in the first quarter. CWM LLC now owns 7,950 shares of the company's stock valued at $29,000 after acquiring an additional 7,898 shares during the last quarter. Legal & General Group Plc raised its stake in Solid Biosciences by 208.6% in the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company's stock valued at $29,000 after acquiring an additional 4,063 shares during the period. Ameritas Investment Partners Inc. raised its stake in Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company's stock valued at $33,000 after acquiring an additional 4,534 shares during the period. Corton Capital Inc. bought a new stake in shares of Solid Biosciences during the fourth quarter valued at about $41,000. Finally, Ground Swell Capital LLC bought a new position in shares of Solid Biosciences in the first quarter valued at approximately $42,000. Hedge funds and other institutional investors own 81.46% of the company's stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.